Patient description: A 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Covid19 Anosmia Fever Cough Shortness of Breath Sore Throat Nausea Vomiting Headache Muscle Weakness Pain, Muscle Pain, Chest Pain, Joint Pain, Abdominal Pain Irritable Mood Confusion Covid-19 positive by polymerase chain reaction (PCR) testing Participant must be able to evaluate their symptoms and report them in the symptoms diary Patients must be able to take their oral temperature daily with an electronic thermometer provided to them with study materials Males and females, at least 18 years of age, capable and willing to provide informed consent Female patient is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile, or is of childbearing potential and practicing at least one method of contraception and preferably two complementary forms of contraception including a barrier method (e.g. male or female condoms, spermicides, sponges, foams, jellies, diaphragm, intrauterine device (IUD)) throughout the study Patient must have received a diagnosis of COVID-19 infection within the last 48 hours and have one or more symptoms Outpatient setting (not currently hospitalized or under immediate consideration for hospitalization) Patient must be able and willing to comply with the requirements of this study protocol  Patient currently hospitalized or under immediate consideration for hospitalization Patient currently in shock or with hemodynamic instability Patient undergoing chemotherapy for cancer Patient is unable to take oral temperature using an electronic thermometer Patient who received at least one dose of the COVID-19 vaccine Female patient who is pregnant or breast-feeding or is considering becoming pregnant during the study People taking anticoagulant/antiplatelet medications, those with bleeding disorders, and people two weeks before or after surgery Patient is considered by the investigator, for any reason, to be an unsuitable candidate for the study Regular consumption of natural products containing more than 150 mg of hesperidin or regular consumption of more than 1 glass of orange juice per day Known allergy to any of the medicinal and non-medicinal ingredient: hesperidin, microcrystalline cellulose, magnesium stearate